TY - JOUR
T1 - A new classification of Diabetic Nephropathy 2014
T2 - a report from Joint Committee on Diabetic Nephropathy
AU - Haneda, Masakazu
AU - Utsunomiya, Kazunori
AU - Koya, Daisuke
AU - Babazono, Tetsuya
AU - Moriya, Tatsumi
AU - Makino, Hirofumi
AU - Kimura, Kenjiro
AU - Suzuki, Yoshiki
AU - Wada, Takashi
AU - Ogawa, Susumu
AU - Inaba, Masaaki
AU - Kanno, Yoshihiko
AU - Shigematsu, Takashi
AU - Masakane, Ikuto
AU - Tsuchiya, Ken
AU - Honda, Keiko
AU - Ichikawa, Kazuko
AU - Shide, Kenichiro
N1 - Funding Information:
Masakazu Haneda has received speaker honoraria from pharmaceutical companies Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Daiichi-Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., Sanofi K.K., Merck Sharp & Dohme, Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Kowa Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K., scholarship grants from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Merck Sharp & Dohme, Boehringer Ingelheim GmbH, and Eli Lilly and Company; Daisuke Koya has received speaker honoraria from pharmaceutical companies Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, and Eli Lilly and Company, research grants from Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, Japan Tabacco Inc., Eli Lilly and Company, and Ono Pharmaceutical Co., Ltd.; Tetsuya Babazono has received speaker honoraria from pharmaceutical company Merck Sharp & Dohme; Tatsumi Moriya has received travel expenses from pharmaceutical companies Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and Daiichi-Sankyo Co., Ltd.; Hirofumi Makino has received speaker honoraria from pharmaceutical companies Teijin Pharma Limited, Chugai Pharmaceutical Co., Ltd., AbbVie GK, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Daiichi-Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Novartis Pharma K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., and Mitsubishi Tanabe Pharma Corporation, research grants from Project for accelerating Practice and Research on Community Medicine in Okayama Prefecture, scholarship grants from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and Mitsubishi Tanabe Pharma Corporation; Kenjiro Kimura has received research grants from pharmaceutical companies Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Limited, Boehringer Ingelheim GmbH, Baxter International Inc., and Sekisui Medical Co., Ltd.; Takashi Wada has received speaker honoraria from pharmaceutical company Daiichi-Sankyo Co., Ltd., scholarship grants from Chugai pharmaceutical Co., Ltd.; Susumu Ogawa has received speaker honoraria from pharmaceutical companies Daiichi-Sankyo Co., Ltd., Eli Lilly and Company, and Novo Nordisk Pharma Ltd., research grants from Daiichi-Sankyo Co., Ltd.; Masaaki Inaba has received speaker honoraria from pharmaceutical companies Bayer Yakuhin, Ltd., Takeda Pharmaceutical Co., Ltd., Merck Sharp & Dohme, Kyowa Hakko Kirin Co., Ltd., and Asahi Kasei Pharma Corporation, research grants from Bayer Yakuhin, Ltd., Kyowa Hakko Kirin Co., Ltd., and Eli Lilly and Company; Yoshihiko Kanno has received scholarship grants from pharmaceutical company Chugai Pharmaceutical Co., Ltd., travel expenses from Abbott Japan Co., Ltd.; Takashi Shigematsu has received research grants from pharmaceutical company Bayer Yakuhin, Ltd.; Kazunori Utsunomiya, Yoshiki Suzuki, Ikuto Masakane, Ken Tsuchiya, Keiko Honda, Kazuko Ichikawa, and Kenichiro Shide have no conflict of interest.
Publisher Copyright:
© 2014, Japanese Society of Nephrology, The Japan Diabetes Society, The Japanese Society for Dialysis Therapy, and Japan Society of Metabolism and Clinical Nutrition.
PY - 2015/2
Y1 - 2015/2
N2 - The Joint Committee on Diabetic Nephropathy has revised its Classification of Diabetic Nephropathy (Classification of Diabetic Nephropathy 2014) in line with the widespread use of key concepts such as the estimated glomerular filtration rate (eGFR) and chronic kidney disease. In revising the Classification, the Committee carefully evaluated, as relevant to current revision, the report of a study conducted by the Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan. Major revisions to the Classification are summarized as follows: (1) eGFR is substituted for GFR in the Classification; (2) the subdivisions A and B in stage 3 (overt nephropathy) have been reintegrated; (3) stage 4 (kidney failure) has been redefined as a GFR less than 30 mL/min/1.73 m2, regardless of the extent of albuminuria; and (4) stress has been placed on the differential diagnosis of diabetic nephropathy versus non-diabetic kidney disease as being crucial in all stages of diabetic nephropathy.
AB - The Joint Committee on Diabetic Nephropathy has revised its Classification of Diabetic Nephropathy (Classification of Diabetic Nephropathy 2014) in line with the widespread use of key concepts such as the estimated glomerular filtration rate (eGFR) and chronic kidney disease. In revising the Classification, the Committee carefully evaluated, as relevant to current revision, the report of a study conducted by the Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan. Major revisions to the Classification are summarized as follows: (1) eGFR is substituted for GFR in the Classification; (2) the subdivisions A and B in stage 3 (overt nephropathy) have been reintegrated; (3) stage 4 (kidney failure) has been redefined as a GFR less than 30 mL/min/1.73 m2, regardless of the extent of albuminuria; and (4) stress has been placed on the differential diagnosis of diabetic nephropathy versus non-diabetic kidney disease as being crucial in all stages of diabetic nephropathy.
KW - Albuminuria
KW - Chronic kidney disease (CKD)
KW - Diabetic nephropathy
KW - Glomerular filtration rate (GFR)
KW - Proteinuria
UR - http://www.scopus.com/inward/record.url?scp=85027951793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027951793&partnerID=8YFLogxK
U2 - 10.1007/s10157-014-1057-z
DO - 10.1007/s10157-014-1057-z
M3 - Review article
C2 - 25527479
AN - SCOPUS:85027951793
SN - 1342-1751
VL - 19
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 1
ER -
